Nanexa
3.67 SEK
-1.35 %
Less than 1K followers
NANEXA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Nanexa
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.4 | 4.5 | 24.4 | 2.9 | 2.7 | 0.5 | 30.1 | 36.1 |
| EBITDA | -1.8 | 0.1 | -15.2 | -5.2 | -2.1 | -8.8 | ||
| EBIT | -4.6 | -12.0 | -26.1 | -8.2 | -5.2 | -12.0 | 16.7 | -8.8 |
| EBIT-% | -70.8 % | -266.2 % | -107.0 % | -285.1 % | -193.4 % | -2,495.8 % | 55.4 % | -24.3 % |
| Profit before taxes | -4.4 | -11.5 | -24.8 | -8,987.0 | -5.9 | -12.6 | 16.0 | -11.5 |
| Net income | -4.4 | -11.6 | -24.9 | -9.0 | -5.9 | -12.5 | 16.0 | -11.4 |